-+ 0.00%
-+ 0.00%
-+ 0.00%

CUE BIOPHARMA REPORTS NEW COMPLETE RESPONSE AND CONFIRMED 50% OVERALL RESPONSE RATE IN ONGOING PHASE 1 TRIAL OF CUE-101 AND PEMBROLIZUMAB IN RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER

Reuters·07/16/2025 12:00:02

Please log in to view news